Cagrilintide – 10 mg

Cagrilintide – 10 mg

Cagrilintide (AM833) is an investigational, long-acting acylated amylin analogue designed for once-weekly subcutaneous injection to treat obesity. It acts as a non-selective amylin receptor (AMYR) and calcitonin receptor (CTR) agonist, reducing food intake and promoting significant weight loss. Clinical trials, such as REDEFINE, are evaluating it, often in combination with semaglutide (CagriSema). 

🧫 Common Research Applications

(High-Level, Non-Medical)

In appropriate laboratory environments, cagrilintide may be referenced for:

• Analytical & Identity Verification

• Peptide identification testing

• Purity and specification confirmation

• Reference material comparison

• Structural & Stability Evaluation

• Molecular structure analysis

• Peptide degradation and integrity profiling

• Environmental stability assessment

• Formulation & Handling Studies

• Non-clinical formulation benchmarking

• Compatibility and handling evaluations

These examples are provided for research context only and do not imply biological activity or use in living systems.

✅ Quality & Testing Standards

The Orderly Blue applies strict quality assurance protocols to all research peptides:

• Compound Type: Research peptide

• Format: Lyophilized research material

• Amount: 10 mg

• Third-Party Tested: ✔ Yes

• Certificate of Analysis (COA): ✔ Included

• Batch Traceability: ✔ Documented

Independent laboratory testing verifies peptide identity and specification alignment prior to release.

🧊 Storage & Handling (Research Context)

To maintain peptide integrity in laboratory environments:

• Store in a cool, dry, controlled environment

• Protect from excess heat, light, and moisture

• Handle using appropriate laboratory PPE

• Avoid contamination or improper handling outside research protocols

Always consult the included Certificate of Analysis (COA) for batch-specific storage and handling guidance.